Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer

Objective To determine how patients with non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1)-negative and/or a low tumor mutation burden status benefit from immune checkpoint inhibitors (ICI). Methods We determined the plasma cell-free DNA profiles of 25 patients with PD-L1-neg...

Full description

Saved in:
Bibliographic Details
Published in:Journal of international medical research 2022-04, Vol.50 (4), p.3000605221093222-3000605221093222
Main Authors: Zhang, Xiaochen, Wang, Yina, Xiang, Jingjing, Zhao, Pan, Xun, Yanping, Zhang, Shirong, Xu, Nong
Format: Article
Language:English
Subjects:
B7-H1 Antigen - genetics
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
DNA Copy Number Variations - genetics
Humans
Immunotherapy
Ligands
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Pre-Clinical Research Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To determine how patients with non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1)-negative and/or a low tumor mutation burden status benefit from immune checkpoint inhibitors (ICI). Methods We determined the plasma cell-free DNA profiles of 25 patients with PD-L1-negative advanced NSCLC before ICI therapy using low-coverage whole-genome sequencing. Results Elevated cell-free copy number variations (CNVs) were associated with progressive disease, with a cutoff CNV score of 0.10 evaluated with an area under the curve of 0.790 in PD-L1-negative NSCLC. CNV changes were also correlated with poor survival. Progression-free survival and overall survival were both significantly shorter in CNVhigh compared with CNVlow patients. Conclusions Cell-free CNV may be a useful peripheral blood biomarker for predicting the response to ICIs in patients with NSCLC.
ISSN:0300-0605
1473-2300
DOI:10.1177/03000605221093222